0000000000225727

AUTHOR

Francesca Ligorio

showing 2 related works from this author

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.

2021

Abstract In tumor-bearing mice, cyclic fasting or fasting-mimicking diets (FMD) enhance the activity of antineoplastic treatments by modulating systemic metabolism and boosting antitumor immunity. Here we conducted a clinical trial to investigate the safety and biological effects of cyclic, five-day FMD in combination with standard antitumor therapies. In 101 patients, the FMD was safe, feasible, and resulted in a consistent decrease of blood glucose and growth factor concentration, thus recapitulating metabolic changes that mediate fasting/FMD anticancer effects in preclinical experiments. Integrated transcriptomic and deep-phenotyping analyses revealed that FMD profoundly reshapes antican…

MaleMyeloidmedicine.medical_treatmentAntineoplastic AgentsBreast NeoplasmsPharmacologyTranscriptomeImmune systemmedicineCytotoxic T cellHumansProspective Studiesbusiness.industryGrowth factorCancerMetabolismFastingMiddle Agedmedicine.diseaseClinical trialmedicine.anatomical_structureTreatment OutcomeOncologyFemalebusinessColorectal NeoplasmsCancer discovery
researchProduct

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness

2021

Simple Summary Breast cancer (BC) is not a single disease, but a group of different tumors, and altered HER2 expression defines a particularly aggressive subtype. Although HER2 pharmacological inhibition has dramatically improved the prognosis of HER2-positive BC patients, there is still an urgent need for improved knowledge of HER2 biology and mechanisms underlying HER2-driven aggressiveness and drug susceptibility. Emerging data suggest that the clinical efficacy of molecularly targeted therapies is related to their ability to target breast cancer stem cells (BCSCs), a population that is not only self-sustaining and able to differentiate into distinct lineages, but also contributes to tum…

cancer stem cellsCancer ResearchBreast cancer Cancer stem cells D16HER2 splice variant Drug resistance Full-length HER2 P95HER2Stemness signaling pathwaysmedicine.medical_treatmentContext (language use)ReviewBiologymedicine.disease_caused16HER2 splice variantMetastasisTargeted therapyfull-length HER2Breast cancerbreast cancerCancer stem cellmedicineskin and connective tissue diseasesp95HER2RC254-282drug resistancestemness signaling pathwaysNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncologyCancer researchStem cellSignal transductionCarcinogenesisCancers
researchProduct